Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

Is Tau Aggregation Toxic or Protective?

(2017) Erin E. Congdon et al.   JOURNAL OF ALZHEIMERS DISEASE

Chaperone-like Antibodies Targeting Misfolded Tau Protein: New Vistas in the Immunotherapy of Neurodegenerative Foldopathies

(2017) Norbert Zilka et al.   JOURNAL OF ALZHEIMERS DISEASE

Increase of BDNF Serum Concentration in Lithium Treated Patients with Early Alzheimer's Disease

(2017) Thomas Leyhe et al.   JOURNAL OF ALZHEIMERS DISEASE

Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β

(2017) Rudy J. Castellani et al.   JOURNAL OF ALZHEIMERS DISEASE

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

(2017) Noel G. Faux et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid Imaging in Aging and Dementia: Testing the Amyloid HypothesisIn Vivo

(2014) G. D. Rabinovici et al.   BEHAVIOURAL NEUROLOGY

Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention

(2012) David H. Cribbs   CNS & Neurological Disorders-Drug Targets

EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study

(2012) B. Vellas et al.   Current Alzheimer Research

Stopping a thief and killer: Alzheimer's disease crisis demands greater commitment to research

(2011) William Thies   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies

(2011) C. A. Lasagna-Reeves et al.   Current Alzheimer Research

Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

(2011) Francesco Panza et al.   Current Alzheimer Research

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

(2011) Francesco Panza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Solanezumab for Alzheimer's disease

(2011) Hossein Samadi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibody-based therapy in Alzheimer's disease

(2011) Refik Pul et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

(2011) Bruno P Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

(2011) Rakez Kayed   Human vaccines & immunotherapeutics

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

(2011) Susann Cattepoel et al.   PLoS One

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease

(2010) Kaj Blennow et al.   Alzheimers & Dementia

The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans

(2010) Michael W. Weiner et al.   Alzheimers & Dementia

Murine models of Alzheimer's disease and their use in developing immunotherapies

(2010) Thomas Wisniewski et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

TAU Aggregation is a Therapeutic Target for Alzheimers Disease

(2010) A. Takashima   Current Alzheimer Research

Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid

(2010) V. Frisardi et al.   Current Alzheimer Research

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

(2010) Moran Boimel et al.   EXPERIMENTAL NEUROLOGY

Bapineuzumab

(2010) Geoffrey A Kerchner et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Current therapeutic targets for the treatment of Alzheimer’s disease

(2010) Joshua D Grill et al.   Expert Review of Neurotherapeutics

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease

(2010) Francesco Panza et al.   Immunotherapy

Aggregation of Detergent-insoluble Tau Is Involved in Neuronal Loss but Not in Synaptic Loss

(2010) Tetsuya Kimura et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden

(2010) John C O'Leary et al.   Molecular Neurodegeneration

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease

(2010) Chiou-Miin Wang et al.   NEUROBIOLOGY OF DISEASE

Tau protein and tau aggregation inhibitors

(2010) Bruno Bulic et al.   NEUROPHARMACOLOGY

T Cells Specifically Targeted to Amyloid Plaques Enhance Plaque Clearance in a Mouse Model of Alzheimer's Disease

(2010) Yair Fisher et al.   PLoS One

Immunization Therapy for Alzheimer Disease: A Comprehensive Review of Active Immunization Strategies

(2010) Takeshi Tabira   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Mechanisms of tau-induced neurodegeneration

(2009) Khalid Iqbal et al.   ACTA NEUROPATHOLOGICA

Immunotherapy targeting Alzheimer's phospho-tau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a mouse model of tauopathy

(2009) Pavan K. Krishnamurthy et al.   Alzheimers & Dementia

Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment

(2009) Ronald B. DeMattos et al.   Alzheimers & Dementia

Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo

(2009) Ryan J. Watts et al.   Alzheimers & Dementia

Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy

(2009) Michal Novak   Alzheimers & Dementia

Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease

(2009) Timothy Nicholas et al.   Alzheimers & Dementia

The ADCS valproate neuroprotection trial: Primary efficacy and safety results

(2009) Pierre N. Tariot et al.   Alzheimers & Dementia

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

Identification of Aminothienopyridazine Inhibitors of Tau Assembly by Quantitative High-Throughput Screening

(2009) Alex Crowe et al.   BIOCHEMISTRY

Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy

(2009) Eva Kontsekova et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

(2009) Rakez Kayed et al.   CURRENT OPINION IN IMMUNOLOGY

Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease

(2009) Francesco Panza et al.   DRUGS & AGING

Targeting Aβ and tau in Alzheimer's disease, an early interim report

(2009) Todd E. Golde et al.   EXPERIMENTAL NEUROLOGY

Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?

(2009) Gregory A Jicha   EXPERT OPINION ON BIOLOGICAL THERAPY

Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?

(2009) Pierre N. Tariot et al.   JOURNAL OF CLINICAL PSYCHIATRY

Lithium Trial in Alzheimer's Disease

(2009) Harald Hampel et al.   JOURNAL OF CLINICAL PSYCHIATRY

Vaccination with A -Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A  and Lowers Plaque Burden in APP Transgenic Mice

(2009) P. Bach et al.   JOURNAL OF IMMUNOLOGY

Tau oligomers and aggregation in Alzheimer’s disease

(2009) Marco A. Meraz-Ríos et al.   JOURNAL OF NEUROCHEMISTRY

Tangle-Bearing Neurons Survive Despite Disruption of Membrane Integrity in a Mouse Model of Tauopathy

(2009) Alix de Calignon et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

A  Immunotherapy: Intracerebral Sequestration of A  by an Anti-A  Monoclonal Antibody 266 with High Affinity to Soluble A 

(2009) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease

(2009) A. L. Southwell et al.   JOURNAL OF NEUROSCIENCE

Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy

(2009) C. Wischik et al.   Journal of Nutrition Health & Aging

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

(2009) Kurt R. Brunden et al.   NATURE REVIEWS DRUG DISCOVERY

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

The Role of Apolipoprotein E in Alzheimer's Disease

(2009) Jungsu Kim et al.   NEURON

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

(2009) M. Britschgi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel therapeutic strategies for neurodegenerative disease

(2009) Hitoshi TANIMUKAI et al.   Psychogeriatrics

O4-01-05: Presenilin 1 mutation promotes Tau phosphorylation and aggregation in a novel Alzheimer's disease mouse model

(2008) Allal Boutajangout et al.   Alzheimers & Dementia

O4-04-04: Tau immunotherapy prevents cognitive decline and clears pathological Tau in a tangle mouse model

(2008) Einar M. Sigurdsson et al.   Alzheimers & Dementia

S1-02-02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin

(2008) Norman R. Relkin   Alzheimers & Dementia

P4-347: Tau aggregation inhibitor (TAI) therapy with rember™ arrests the trajectory of rCBF decline in brain regions affected by Tau pathology in mild and moderate Alzheimer's disease (AD)

(2008) Roger T. Staff et al.   Alzheimers & Dementia

P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease

(2008) Eric R. Siemers et al.   Alzheimers & Dementia

P4-384: Tau Aggregation Inhibitor (TAI) therapy with rember™ changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD)

(2008) Alison D. Murray et al.   Alzheimers & Dementia

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

(2008) Claude M. Wischik et al.   Alzheimers & Dementia

A nasal proteosome adjuvant activates microglia and prevents amyloid deposition

(2008) Dan Frenkel et al.   ANNALS OF NEUROLOGY

Active and Passive Immunotherapy for Neurodegenerative Disorders

(2008) David L. Brody et al.   Annual Review of Neuroscience

Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior

(2008) Dennis J. Selkoe   BEHAVIOURAL BRAIN RESEARCH

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

(2008) D. Boche et al.   BRAIN

Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease

(2008) C.-X. Gong et al.   CURRENT MEDICINAL CHEMISTRY

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics

(2008) Hanna Rosenmann et al.   EXPERIMENTAL NEUROLOGY

Immunotherapy Reduces Vascular Amyloid-  in PDAPP Mice

(2008) S. Schroeter et al.   JOURNAL OF NEUROSCIENCE

Interplay between Cyclin-Dependent Kinase 5 and Glycogen Synthase Kinase 3  Mediated by Neuregulin Signaling Leads to Differential Effects on Tau Phosphorylation and Amyloid Precursor Protein Processing

(2008) Y. Wen et al.   JOURNAL OF NEUROSCIENCE

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Amyloid-β immunisation for Alzheimer's disease

(2008) Thomas Wisniewski et al.   LANCET NEUROLOGY

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

Animal models of Alzheimer's disease and frontotemporal dementia

(2008) Jürgen Götz et al.   NATURE REVIEWS NEUROSCIENCE

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING

Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse

(2008) Peter Seubert et al.   Neurodegenerative Diseases

Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

(2008) Michael Pride et al.   Neurodegenerative Diseases

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

(2008) Scott A. Small et al.   NEURON

Tau-based treatment strategies in neurodegenerative diseases

(2008) Anja Schneider et al.   Neurotherapeutics

Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy

(2008) Nina Movsesyan et al.   PLoS One

Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools

(2007) Peter Lichtlen et al.   JOURNAL OF NEUROCHEMISTRY

Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide

(2003) Merav Bassan et al.   JOURNAL OF NEUROCHEMISTRY